Please try another search
PARIS - Following Ipsen's recent Capital Markets Day, UBS has reiterated its Buy rating on the French pharmaceutical company, setting a price target of €150. This target suggests a significant...
By Bhanvi Satija and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration (FDA) on Wednesday approved French drugmaker Ipsen's drug for a rare bone disorder, making it the first treatment...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review